echemi logo
Product
  • Product
  • Supplier
  • Inquiry
    Home > Medical News > Medical World News > Research and development daily oral PD-L1 first domestic new drug approved clinical

    Research and development daily oral PD-L1 first domestic new drug approved clinical

    • Last Update: 2019-11-14
    • Source: Internet
    • Author: User
    Search more information of high quality chemicals, good prices and reliable suppliers, visit www.echemi.com
    GSK nucala critical phase III successfully became the first treatment drug to significantly reduce hes flare; the gospel of type 2 diabetes! Key phase III clinical success of dorzagliatin! The first domestic new drug of oral PD-L1 has been approved for clinical use; Junshi biological "adamumumab" has been reported as the fifth domestic drug on the market We focus on the latest development of pharmaceutical research and development, and provide timely and accurate information reference for R & D personnel On November 13, GSK released the positive results of the key phase III clinical study of nucala in the treatment of eosinophilic syndrome (HES) According to the results of this study, nucala is the first drug to show a reduction in HES flares in the treatment of this rare disease, which has the potential to change the treatment pattern of HES patients GSK has planned to submit a new application for nucala treatment of HES in 2020 Lilly Brigham diabetes alliance recently announced the launch of phase III empulse study (nct04157751), the sixth phase III study in the heart failure project of SGLT2 inhibitor jardiance (empagliflozin) The study will assess whether initiating a 10mg daily dose of jardiance in the hospital once the condition is stable improves the outcome of heart failure in patients hospitalized for any type of acute heart failure event Hualing pharmaceutical recently announced the 24 week top line results of the first phase III clinical study of the double mechanism glucokinase activator dorzagliatin (hms5552) Dorzagliatin is based on the global leading scientific concept of glucokinase (GK) as a blood glucose sensor, which plays a core role in the regulation of blood glucose homeostasis The treatment of type 2 diabetes can be realized by repairing the GK function of the patients with type 2 diabetes and remodeling the blood glucose homeostasis On November 14, HongRi pharmaceutical announced that it had received the notice of clinical trial from the drug regulatory bureau, saying that the innovative drug emdifen tablets it applied for met the relevant requirements of drug clinical trial review and approval, was approved to carry out the clinical trial of solid tumor, and will carry out the clinical trial in the near future Emdifen tablet is a PD-L1 inhibitor developed by HongRi pharmaceutical industry, and it is also the first oral PD-L1 small molecule inhibitor approved by clinical trials in China On November 14, the official CDE website showed Lilly submitted the application for listing of breast cancer drug abemaciclib Abemaciclib was initially approved by FDA in September 2017 for single drug treatment of ER + / HER2 - advanced or metastatic breast cancer that had undergone endocrine therapy and disease progression after chemotherapy, or for combination with fluvectin second-line treatment of HR +, HER2 - advanced or transitional breast cancer that had undergone endocrine therapy On November 13, Junshi biological "adamumumab injection" was accepted by the drug examination center (acceptance No.: cxss1900041), becoming the fourth domestic enterprise to submit the listing application, among which the first domestic adamumumab biological similar drug of baiaotai was just approved for listing on November 7 Sansheng pharmaceutical announced that the clinical trial application of hif-117 capsule (sss17) for anemia treatment of patients with chronic kidney disease was approved by the State Drug Administration on November 12, 2019 At present, the clinical trial work of the product is in active preparation Recently, Jincheng pharmaceutical announced that Jincheng JinSu, a holding subsidiary, received the acceptance notice of consistency evaluation of ceftriaxone sodium for injection issued by the State Food and drug administration Ceftriaxone sodium is a long-acting, broad-spectrum third-generation semi synthetic cephalosporin antibiotic According to the data of minenet, the sales volume of ceftriaxone sodium for terminal injection in public medical institutions in China in 2018 was 3.464 billion yuan, an increase of 21.21% year on year On November 13, Merck, a global research pharmaceutical company, announced the acquisition of calporta, a biotech start-up Under the terms of the agreement, Merck will pay calporta $576 million, including undisclosed advances and milestone payments Through this acquisition, Merck obtained the use of calporta preclinical trpml1 agonist, which is considered as a potential therapy for neurodegenerative diseases such as Alzheimer's disease or Parkinson's disease On November 13, Fosun Pharmaceutical announced that Fosun Pharmaceutical, a holding subsidiary of Fosun Pharmaceutical, had signed a license agreement with mimivax on November 12 Mimivax authorized Fosun Pharmaceutical to use its exclusive know-how and patent in the treatment and prevention of glioblastoma and other tumors and non tumor indications in the region (i.e mainland China, Hong Kong and Macao SAR) Bed development and commercialization of its tumor immunotherapy product survaxm.
    This article is an English version of an article which is originally in the Chinese language on echemi.com and is provided for information purposes only. This website makes no representation or warranty of any kind, either expressed or implied, as to the accuracy, completeness ownership or reliability of the article or any translations thereof. If you have any concerns or complaints relating to the article, please send an email, providing a detailed description of the concern or complaint, to service@echemi.com. A staff member will contact you within 5 working days. Once verified, infringing content will be removed immediately.

    Contact Us

    The source of this page with content of products and services is from Internet, which doesn't represent ECHEMI's opinion. If you have any queries, please write to service@echemi.com. It will be replied within 5 days.

    Moreover, if you find any instances of plagiarism from the page, please send email to service@echemi.com with relevant evidence.